tegafur has been researched along with Fatigue in 22 studies
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 9.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 7.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 7.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 6.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 5.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades." | 3.88 | S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 3.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 3.01 | Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021) |
| "Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | 2.84 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
| "The primary objective of this Phase I study was to assess the safety and tolerability of the vascular endothelial growth factor signalling inhibitor cediranib in combination with cisplatin plus an oral fluoropyrimidine, in Japanese patients with previously untreated advanced gastric cancer." | 2.77 | Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. ( Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y, 2012) |
| "Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable." | 2.73 | Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. ( Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB, 2008) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 2.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "Irinotecan was given intravenously over the course of 90 min on day 1 and S-1 was given orally from days 1 to 14 of a 21-day cycle." | 2.71 | Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H, 2003) |
| " Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day." | 2.68 | Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996) |
| " Severe adverse events were observed in 22 patients (91." | 1.42 | Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck. ( Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Hirahara, N | 1 |
| Matsubara, T | 1 |
| Kaji, S | 1 |
| Yamamoto, T | 1 |
| Hyakudomi, R | 1 |
| Takai, K | 1 |
| Ishitobi, K | 1 |
| Uchida, Y | 1 |
| Tajima, Y | 1 |
| Kudo, M | 1 |
| Moriguchi, M | 1 |
| Numata, K | 1 |
| Hidaka, H | 1 |
| Tanaka, H | 1 |
| Ikeda, M | 2 |
| Kawazoe, S | 1 |
| Ohkawa, S | 1 |
| Sato, Y | 1 |
| Kaneko, S | 1 |
| Furuse, J | 2 |
| Takeuchi, M | 2 |
| Fang, X | 1 |
| Date, Y | 1 |
| Okusaka, T | 2 |
| Winther, SB | 2 |
| Bjerregaard, JK | 1 |
| Schonnemann, KR | 1 |
| Ejlsmark, MW | 1 |
| Krogh, M | 2 |
| Jensen, HA | 2 |
| Pfeiffer, P | 2 |
| Takahara, N | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Sasaki, T | 2 |
| Ishigami, H | 1 |
| Yamashita, H | 1 |
| Yamaguchi, H | 1 |
| Hamada, T | 2 |
| Uchino, R | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Mohri, D | 1 |
| Kawakubo, K | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Kitayama, J | 1 |
| Watanabe, T | 2 |
| Koike, K | 1 |
| Suzuki, S | 1 |
| Honda, K | 1 |
| Sato, T | 1 |
| Yamazaki, K | 2 |
| Ishikawa, K | 1 |
| Takashima, T | 1 |
| Mukai, H | 1 |
| Hara, F | 1 |
| Matsubara, N | 1 |
| Saito, T | 1 |
| Takano, T | 1 |
| Park, Y | 1 |
| Toyama, T | 1 |
| Hozumi, Y | 1 |
| Tsurutani, J | 1 |
| Imoto, S | 1 |
| Sagara, Y | 1 |
| Nishimura, R | 1 |
| Shimozuma, K | 1 |
| Ohashi, Y | 1 |
| Zubcevic, K | 1 |
| Qvortrup, C | 1 |
| Vestermark, LW | 1 |
| Sorbye, H | 1 |
| Park, SH | 1 |
| Kim, YS | 1 |
| Hong, J | 1 |
| Park, J | 1 |
| Nam, E | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 1 |
| Lee, WK | 1 |
| Chung, M | 1 |
| Oh, DY | 1 |
| Cha, Y | 1 |
| Choi, IS | 2 |
| Yoon, SY | 1 |
| Choi, IK | 1 |
| Kim, JH | 2 |
| Oh, SC | 1 |
| Kim, CD | 1 |
| Kim, JS | 1 |
| Bang, YJ | 1 |
| Kim, YH | 1 |
| Koizumi, W | 1 |
| Akiya, T | 1 |
| Sato, A | 1 |
| Sakuyama, T | 1 |
| Sasaki, E | 1 |
| Tomidokoro, T | 1 |
| Fujimori, M | 1 |
| Kikuchi, Y | 1 |
| Shimada, K | 1 |
| Mine, T | 1 |
| Yamaguchi, K | 1 |
| Kurihara, M | 1 |
| Lee, KW | 1 |
| Kim, KH | 1 |
| Kim, YJ | 1 |
| Lee, JS | 1 |
| Hsu, CH | 1 |
| Shen, YC | 1 |
| Lin, ZZ | 1 |
| Chen, PJ | 1 |
| Shao, YY | 1 |
| Ding, YH | 1 |
| Hsu, C | 1 |
| Cheng, AL | 1 |
| Tsushima, T | 1 |
| Hironaka, S | 1 |
| Boku, N | 2 |
| Machida, N | 1 |
| Yasui, H | 2 |
| Taku, K | 2 |
| Fukutomi, A | 1 |
| Onozawa, Y | 1 |
| Satoh, T | 1 |
| Yamada, Y | 2 |
| Muro, K | 2 |
| Hayashi, H | 1 |
| Shimada, Y | 2 |
| Takahari, D | 1 |
| Nakajima, TE | 1 |
| Shi, X | 1 |
| Brown, KH | 1 |
| Kimura, Y | 1 |
| Yano, H | 1 |
| Imamura, H | 1 |
| Fujitani, K | 1 |
| Imano, M | 1 |
| Tokunaga, Y | 1 |
| Matsuoka, M | 1 |
| Kurokawa, Y | 1 |
| Shimokawa, T | 1 |
| Takiuchi, H | 1 |
| Tsujinaka, T | 1 |
| Furukawa, H | 1 |
| Goto, A | 1 |
| Arai, T | 1 |
| Ura, T | 1 |
| Hamaguchi, T | 1 |
| Shirao, K | 1 |
| Chen, YM | 1 |
| Perng, RP | 1 |
| Tsai, CM | 1 |
| Whang-Peng, J | 1 |
| Funakoshi, A | 1 |
| Yamao, K | 1 |
| Nagase, M | 1 |
| Ishii, H | 1 |
| Nakachi, K | 1 |
| Ueno, H | 1 |
| Morizane, C | 1 |
| Horikawa, Y | 1 |
| Mizuno, N | 1 |
| Miyake, Y | 1 |
| Iwasaki, Y | 1 |
| Shiraha, H | 1 |
| Sakaguchi, K | 1 |
| Shiratori, Y | 1 |
| Muggia, FM | 1 |
| Wu, X | 1 |
| Spicer, D | 1 |
| Groshen, S | 1 |
| Jeffers, S | 1 |
| Leichman, CG | 1 |
| Leichman, L | 1 |
| Chan, KK | 1 |
| Bokemeyer, C | 1 |
| Hartmann, JT | 1 |
| Mayer, F | 1 |
| Böhlke, I | 1 |
| Kanz, L | 1 |
| Von Pawel, J | 1 |
| Derigs, G | 1 |
| Schröder, M | 1 |
| Colevas, AD | 1 |
| Amrein, PC | 1 |
| Gomolin, H | 1 |
| Barton, JJ | 1 |
| Read, RR | 1 |
| Adak, S | 1 |
| Benner, S | 1 |
| Costello, R | 1 |
| Posner, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 trials available for tegafur and Fatigue
| Article | Year |
|---|---|
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2021 |
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru | 2017 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2016 |
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2008 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatig | 2010 |
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Fema | 2010 |
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2010 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2010 |
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antime | 2010 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian Peopl | 2012 |
A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2013 |
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dru | 2003 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2006 |
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor | 1996 |
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Re | 2000 |
A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antin | 2001 |
3 other studies available for tegafur and Fatigue
| Article | Year |
|---|---|
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2018 |
Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemot | 2015 |
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2007 |